VivoSeq
Other

T Cell

2

Pipeline Programs↗

6

Active Trials↗

4

Companies Involved↗

T Cell is an early-stage landscape with 2 programs across 4 companies. The most active players are Sanofi, Pfizer, Cullinan Therapeutics Inc..

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1Pfizer logo

Pfizer

0 programs

PreclinicalC

Cullinan Therapeutics Inc.

0 programs

PreclinicalH

Hebei Senlang Biotechnology Inc., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Cyclophosphamide

Baxter Healthcare Corporation

Fludarabine

Sanofi

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSCell therapy133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

22

clinical trials

Completed9 · 41%
Recruiting6 · 27%
Unknown status5 · 23%
Terminated2 · 9%

Clinical Trials

Trial Activity

22 trials

Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06575374·36 enrolled
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Recruiting·CCullinan Therapeutics Inc.·Phase 1·NCT07041099·36 enrolled
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Recruiting·UUniversity of California, San Francisco·Phase 4·NCT05858645·25 enrolled
The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY
Recruiting·UUniversity of Toronto·N/A·NCT06823596·26 enrolled
A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT07055477·60 enrolled
Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products
Recruiting·SSeattle Children's Hospital·N/A·NCT07424157·500 enrolled
RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
Completed·—·Phase 1·NCT05902845·4 enrolled
HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC
Completed·UUniversity of Pittsburgh·N/A·NCT02038335·451 enrolled
Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response
Completed·KKirby Institute·Phase 4·NCT00772590·75 enrolled
Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)
Completed·GGenetic Immunity·N/A·NCT00918840·16 enrolled
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
Completed·Pfizer logoPfizer·Phase 3·NCT00712348·31 enrolled
Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
Completed·Pfizer logoPfizer·Phase 3·NCT00705939·45 enrolled
Effect of Boceprevir on HCV-specific T Cell Responses
Completed·AAzienda Ospedaliero-Universitaria di Parma·N/A·NCT01403181·30 enrolled
Allogeneic Virus-specific T Cell Lines (VSTs)
Completed·—·Phase 1·NCT02510417·31 enrolled
Chloroquine as a Modulator of T Cell Immune Activation
Completed·CCIHR Canadian HIV Trials Network·N/A·NCT02004314·19 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)